Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05571839 · View on ClinicalTrials.gov ↗
Study Summary
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.
Conditions Studied
Interventions
- DRUG PF-08046049
Study Locations (20)
California
- UCLA Hematology/Oncology - Administrative Office — Los Angeles
- The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate — Los Angeles
- Cedars-Sinai Medical Center — Los Angeles
- Ronald Reagan UCLA Medical Center, Drug Information Center — Los Angeles
- UCLA Hematology/Oncology — Los Angeles
- UCLA Hematology/ Oncology- Pasadena — Pasadena
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco
- UCSF Medical Center, Investigational Pharmacy — San Francisco
- UCLA Hematology/Oncology - Santa Barbara — Santa Barbara
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-up only) — Santa Monica
- UCLA Hematology - Oncology Clinic - Westlake Village — Westlake Village
Colorado
- Quest Diagnostics Incorporated - Denver — Denver
- Presbyterian/St. Lukes Medical Center — Denver
Illinois
- Northwestern Medical Group — Chicago
- Northwestern Memorial Hospital — Chicago
Massachusetts
- BWH — Boston
- Dana-Farber Cancer Institute (DFCI) — Boston
New York
- Ambulatory Care Center at NYU Langone Medical Center — New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York
New Jersey
- Laboratory Corporation of America — Raritan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2026-06-06 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05571839
The ClinicalTrials.gov registry entry for NCT05571839 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which PF-08046049 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05571839 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Colorado, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05571839 about?
NCT05571839 is a clinical study titled "A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors". This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the...
What is the current status of trial NCT05571839?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-01-03. Estimated completion is 2026-06-06.
What conditions does trial NCT05571839 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer, Colorectal Neoplasms, Mesothelioma, Pancreatic Neoplasms, Cutaneous Melanoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05571839?
The interventions under investigation include: PF-08046049 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05571839?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05571839 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.